Related Experiment Video
Updated: Apr 30, 2026
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: February 23, 2024
Using Caenorhabditis elegans as a Model for Obesity Pharmacology Development
Jolene Zheng1, Joseph R Vasselli, Jason F King
11Department of Food Science, College of Agricultural Center, Louisiana State University, Baton Rouge, LA; 2Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA; 3Columbia University, New York, NY; 4Department of Biological Science, College of Sciences, Louisiana State University, Baton Rouge, LA; 5Department of Environment, School of Life Sciences, Fudan University, Shanghai, China; and 6University of California, Davis One Shields Avenue Davis, CA.
Abstract:
The Caenorhabditis elegans model is a rapid and inexpensive method to address pharmacologic questions. We describe the use of C. elegans to explore 2 pharmacologic questions concerning candidate antiobesity drugs and illustrate its potential usefulness in pharmacologic research: (1) to determine a ratio of betahistine-olanzapine that blocks the olanzapine-induced intestinal fat deposition (IFD) as detected by Nile red staining and (2) to identify the mechanism of action of a pharmaceutical candidate AB-101 that reduces IFD. Olanzapine (53 μg/mL) increased the IFD (12.1 ± 0.1%, P < 0.02), which was blocked by betahistine (763 μg/mL, 39.3 ± 0.01%, P < 0.05) in wild-type C. elegans (N2). AB-101 (1.0%) reduced the IFD in N2 (P < 0.05), increased the pharyngeal pumping rate (P < 0.05), and reversed the elevated IFD induced by protease inhibitors atazanavir and ritonavir (P < 0.05). AB-101 did not affect IFD in a ACS null mutant strain acs-4(ok2872) III/hT2[bli-4(e937) let-?(q782) qIs48](I;III) suggesting an involvement of the lipid oxidation pathway and an upregulation of CPT-1. Our studies suggest that C. elegans may be used as a resource in pharmacologic research. This article is intended to stimulate a greater appreciation of its value in the development of new pharmaceutical interventions.
